Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid ...
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoi...
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2010-02-17
- Lead Sponsor
- Korean Breast Cancer Study Group
- Target Recruit Count
- 237
- Registration Number
- NCT00912938
- Locations
- 🇰🇷
Department of Surgery, Korea University Guro Hospital, Seoul, Korea, Republic of
A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausal Osteoporosis (PMO) Patients Between the Ages of 50 and 65 Years
- First Posted Date
- 2009-05-29
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 118
- Registration Number
- NCT00909961
- Locations
- 🇹🇷
Novartis Investigative site, Konya, Turkey
🇹🇷Novartis Investigational site, Istanbul, Turkey
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-05-18
- Last Posted Date
- 2016-04-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 17
- Registration Number
- NCT00903162
- Locations
- 🇺🇸
University of Colorado, Denver, Colorado, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Newton Wellesley Hospital, Newton, Massachusetts, United States
Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
- First Posted Date
- 2009-05-11
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 419
- Registration Number
- NCT00896532
Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer
- First Posted Date
- 2009-05-04
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 24
- Registration Number
- NCT00892242
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)
- First Posted Date
- 2009-04-29
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT00889590
- Locations
- 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
🇧🇪University hospital Gent, Gent, Belgium
🇳🇱Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2009-04-21
- Last Posted Date
- 2023-04-10
- Target Recruit Count
- 29
- Registration Number
- NCT00885326
- Locations
- 🇨🇦
CHU Sainte Justine, Montreal, Quebec, Canada
🇺🇸Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States
🇺🇸Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States
A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
- Conditions
- Interventions
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT00879034
- Locations
- 🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States
S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307
- Conditions
- First Posted Date
- 2009-04-02
- Last Posted Date
- 2013-04-10
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00873808
- Locations
- 🇺🇸
University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1822
- Registration Number
- NCT00869206
- Locations
- 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸CCOP - Columbus, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.